Bone loss with exemestane: Is the jury still out?

J Clin Oncol. 2005 Dec 20;23(36):9433-4; author reply 9433-5. doi: 10.1200/JCO.2005.04.1376.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Androstadienes / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Bone Density / drug effects*
  • Breast Neoplasms
  • Female
  • Femur
  • Humans
  • Postmenopause
  • Reproducibility of Results

Substances

  • Androstadienes
  • Antineoplastic Agents
  • exemestane